Werewolf Therapeutics to Present at Upcoming Conferences in November 2021

Rhea-AI Summary

Werewolf Therapeutics (Nasdaq: HOWL), a pioneering biopharmaceutical company, has announced management will present at two key investor conferences this month. The Jefferies Global Healthcare Conference is scheduled for November 18th at 3:00 AM EST, followed by the Evercore ISI HealthCONx Conference on November 30th at 10:30 AM EST. The webcasts will be available on their investor relations webpage. The company aims to advance its innovative INDUKINE™ therapeutics, designed to activate the immune system against cancer, particularly through products WTX-124 and WTX-330.

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present at the following investor conferences:

Jefferies Global Healthcare Conference on Thursday, November 18th at 3:00am EST

Evercore ISI HealthCONx Conference on Tuesday, November 30th at 10:30am EST

Access to the live webcast of these events, as well as an archived recording, will be available under the “Events” tab on the investor relations section of the Werewolf Therapeutics website at: https://investors.werewolftx.com/news-and-events/events.

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

To learn more visit  https//werewolftx.com.

Investor Contact:
Jonathan Nugent
Managing Director
Stern IR
jonathan.nugent@sternir.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com 

Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com

FAQ

What is Werewolf Therapeutics presenting at the Jefferies Global Healthcare Conference?

Werewolf Therapeutics will present at the Jefferies Global Healthcare Conference on November 18th at 3:00 AM EST.

When is the Evercore ISI HealthCONx Conference presentation for Werewolf Therapeutics?

The Evercore ISI HealthCONx Conference presentation for Werewolf Therapeutics is on November 30th at 10:30 AM EST.

Where can I watch the Werewolf Therapeutics investor conference webcasts?

The webcasts for Werewolf Therapeutics investor conferences will be available under the 'Events' tab on their investor relations website.

What are the main products of Werewolf Therapeutics?

Werewolf Therapeutics is focused on their INDUKINE™ therapeutics, specifically WTX-124 and WTX-330, designed to treat solid tumors.

What is the ticker symbol for Werewolf Therapeutics?

The ticker symbol for Werewolf Therapeutics is HOWL.